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Quinazolines are nitrogen containing heterocyclic scaffolds
and have showed a wide range biological activities, such
as anticancer (Connell, 2004; Marvania et al., 2011),
antitubercular (Jampilek et al., 2009), anti-inflammatory
(Laddha and Bhatnagar, 2009), antimicrobial (McLaughlin
and Evans, 2010), and anti-HIV (Selvam et al., 2010) activities.
The quinazoline based molecules were found to inhibit the
epidermal growth factor receptor (EGFR) tyrosine kinase
(Kersemaekers et al., 1999; Maurizi et al., 1996). Some of
the quinazoline based compounds are used as anticancer
drugs, such as Gefitinib (1) (Murphy and Stordal, 2011; Sunet al., 2011) and Erlotinib (2) (Herbst, 2003). Both
these compounds are first-generation EGFR-targeting
4-anilinoquinazoline chemotherapeutics and used to treat
non-small cell lung cancer. Further, many quinazoline
derivatives show antitumor activity through inhibition of
several potential anticancer targets such as checkpoint H
kinase 2 (Caldwell et al., 2011), non-receptor protein tyrosine
kinase JAK2 (Yang et al., 2011), poly(ADP-ribose)
polymerase (Hattori et al., 2004) and peptidylprolyl cis/trans
isomerase Pin1 (Zhu et al., 2011).
Similarly, chalcones are well-known intermediates for
synthesizing various heterocyclic compounds. Chalcones
represent an important naturally occurring a,b-unsaturated
ketones and showed a wide spectra of biological activities, such
as antitumor (Modzelewska et al., 2006), antifungal (Lahtchev
et al., 2008), antibacterial (Zangade et al., 2010), and
anti-inflammatory (Won et al., 2005). The naturally occurring
E-resveratrol (3) is a natural stilbene derivative that occurs in
various edible plants such as grapes and nuts (Jang et al.,
1997). It possesses multiple biological activities, those include
anticancer (Fulda, 2010), antioxidant (Creasy and Coffee,Journal
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Figure 1 Structures of as Gefitinib (1), Erlotinib (2) and E-resveratrol (3).
2 S. Madhavi et al.1988), anti-inflammatory (Uenobe et al., 1997), and liver pro-
tecting (Virgili and Contestabile, 2000). The structures of anti-
cancer drugs Gefitinib (1), Erlotinib (2) and E-resveratrol (3)
are shown in Fig. 1.
In view of biological importunacy of quinazoline and chal-
cones, we have designed and synthesized a series of chalcone
incorporated quinazoline derivatives (11a–11j). Further, these
derivatives were evaluated for their anticancer activity. All
the synthesized compounds were evaluated for their anticancer
activities against four human cancer cell lines (A549, HT-29,
MCF-7 and A375). Among them, four compounds, 11f, 11g,
11i and 11j showed more potent anticancer activity than the
control drug, Combretastatin-A4.
2. Experimental
2.1. General
All chemicals and reagents were obtained from Aldrich
(Sigma–Aldrich, St. Louis, MO, USA), Lancaster (Alfa Aesar,
Johnson Matthey Company, Ward Hill, MA, USA) and were
used without further purification. Reactions were monitored
by TLC, performed on silica gel glass plates containing 60
F-254, and visualization on TLC was achieved by UV light
or iodine indicator. 1H and 13C NMR spectra were
recorded on Gemini Varian-VXR-unity and Bruker
UXNMR/XWIN-NMR (400 and 300 MHz) instrument.
Chemical shifts (d) are reported in ppm downfield from inter-
nal TMS standard. ESI spectra were recorded on Micro mass,
Quattro LC using ESI+ software with capillary voltage
3.98 kV and ESI mode positive ion trap detector. Melting
points were determined with an electro thermal melting point
apparatus, and are uncorrected.
2.2. Synthesis of quinazolin-4-ol (6)
A mixture of anthranilic acid (4) (13 g, 94.7 mmol) was
heated with formamide (5) (42 g, 94.7 mmol) in absolute
ethanol at 65 C for 4 h. Then it was cooled at room temper-
ature. The mixture solidified. It was broken up and mixed
with water and then filtered. The residue was crystallized
from ethanol to afford pure compound 6, 10.8 g in 78% in
yield. Mp: 212–213; 1H NMR (300 MHz, CDCl3):
d 7.10–7.31 (m, 2H), 8.34–8.43 (s, 2H), 8.73 (s, 1H), 9.12
(bs, 1H); MS (FAB): 146 [M]+.
2.3. Synthesis of 4-chloroquinazoline (7)
The quinazolin-4-ol (6) (9 g) was dissolved in 50 mL POCl3 in
a round bottom flask. The mixture was heated on an oil bath
at 120 C for 4 h by which time all the solid had dissolved andPlease cite this article in press as: Madhavi, S. et al., Synthesis of chalcone incorpora
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were removed under reduced pressure. The viscous oily mass
was added continuously to ice-cold liquor ammonia. The pre-
cipitated materials were filtered and extracted with petroleum
ether. The solid, thus obtained, was recrystallized from
petroleum ether respectively to afford pure compound 7,
8.2 g in 81% in yield. Mp: 97–98 C; 1H NMR (400 MHz,
DMSO-d6): d 7.61–7.69 (m, 1H), 7.79–7.83 (m, 1H),
7.90–7.99 (m, 1H), 8.16–8.18 (m, 1H), 8.79 (s, 1H); MS
(FAB): 164 [M]+.
2.4. Synthesis of 4-(quinazolin-4-ylamino)benzaldehyde (9)
Compound 4-chloroquinazoline (7) (8 g, 48.7 mmol) was
dissolved in 20 ml of N-methylpyrrolidine (NMP) and
4-aminobenzaldehyde (8) (5.9 g, 48.7 mmol) was added to this
solution; reaction mixtures were heated at 60 C and after that
4 drops of conc HCl were added and reaction mixtures were
heated for 1 h. After heating the crystalline precipitate was
separated by filtration and purified by recrystallization from
ethanol to afford pure compound 9, 9.4 g in 77% yield. Mp:
104–106 C; 1H NMR (400 MHz, DMSO-d6): d 7.56 (d, 2H,
J= 7.89 Hz), 7.65–7.70 (m, 1H), 7.73–7.76 (m, 1H),
7.78–7.81 (m, 1H), 8.14–8.24 (m, 3H), 8.82 (s, 1H), 8.90 (s,
1H), 9.71 (s, 1H); MS (FAB): 249 [M]+.
2.4.1. Synthesis of (E)-1-Phenyl-3-(4-(quinazolin-4-ylamino)
phenyl)prop-2-en-1-one (11a)
The compound 4-(quinazolin-4-ylamino)benzaldehyde (3)
(400 mg, 1.60 mmol) was dissolved in 5 mL of ethanol, fol-
lowed by addition of acetophenone (10a) (0.18 mL,
1.60 mmol) and 3 drops of piperidine. The reaction mixture
was heated under reflux for 6 h. After cooling water (20 mL)
was added slowly. The crystalline precipitate was separated
by filtration and purified by recrystallization from ethanol to
afford pure compound 11a, 421 mg in 75% yield. Mp:
110–112 C; 1H NMR (400 MHz, DMSO-d6): d 7.25 (d, 1H,
J= 15.6 Hz), 7.34–7.45 (m, 3H), 7.67–7.78 (m, 7H), 7.83
(t, 1H), 8.23 (d, 2H, J= 8.21 Hz), 8.47 (d, 1H,
J= 7.23 Hz), 8.77 (s, 1H), 9.23 (s, 1H); 13C NMR
(400 MHz, DMSO-d6): d 110.6, 118.5, 121.8, 122.4, 129.3,
130.4, 131.7, 132.8, 132.9, 134.5, 134.8, 139.6, 143.6, 145.4,
155.7, 160.2, 165.4, 181.6; MS (ESI): 352 [M+H]+.
2.4.2. Synthesis of (E)-1-(3-Chlorophenyl)-3-(4-(quinazolin-4-
ylamino)phenyl)prop-2-en-1-one (11b)
The compound 11b was prepared following the
method described for the preparation of the compound 11a,
employing 4-(quinazolin-4-ylamino)benzaldehyde (3)
(400 mg, 1.60 mmol) and 3-chloroacetophenone (10b)
(0.2 mL, 1.60 mmol) to afford pure compound 11b, 441 mgted quinazoline derivatives as anticancer agents. Saudi Pharmaceutical Journal
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d6): d 7.29 (d, 1H, J= 15.8 Hz), 7.41 (t, 1H), 7.46 (d, 2H,
J= 8.34 Hz), 7.54–7.59 (m, 3H), 7.78–7.85 (m, 3H), 7.90 (t,
1H), 7.94–7.98 (m, 2H), 8.47–8.50 (m, 1H), 8.83 (s, 1H), 9.34
(s, 1H); 13C NMR (400 MHz, DMSO-d6): d 111.2, 118.6,
122.4, 124.3, 130.3, 131.5, 133.8, 134.1, 134.6, 134.9, 135.3,
135.8, 136.4, 140.3, 143.5, 146.8, 155.4, 160.7, 164.7, 184.2;
MS (ESI): 386 [M+H]+.
2.4.3. Synthesis of (E)-1-(4-Chlorophenyl)-3-(4-(quinazolin-4-
ylamino)phenyl)prop-2-en-1-one (11c)
The compound 11c was prepared following the method
described for the preparation of the compound 11a, employing
4-(quinazolin-4-ylamino)benzaldehyde (3) (400 mg, 1.60 mmol)
and 4-chloroacetophenone (10c) (0.2 mL, 1.60 mmol) to afford
pure compound 11c, 462 mg in 75% yield. Mp: 120–122 C; 1H
NMR (400 MHz, DMSO-d6): d 7.31 (d, 1H, J= 15.7 Hz), 7.38
(d, 2H, J= 8.23 Hz), 7.62 (d, 2H, J= 8.62 Hz), 7.89–7.98 (m,
5H), 8.45 (t, 1H), 8.78 (d, 2H, J= 8.62 Hz), 8.89 (d, 1H,
J= 1.23 Hz), 8.96 (s, 1H), 9.36 (s, 1H); 13C NMR (400 MHz,
DMSO-d6): d 111.8, 118.9, 122.7, 124.9, 130.4, 132.3, 133.7,
134.2, 134.6, 135.8, 138.3, 141.7, 143.8, 146.9, 156.4, 161.6,
165.8, 184.9; MS (ESI): 386 [M+H]+.
2.4.4. Synthesis of (E)-1-(4-Bromophenyl)-3-(4-(quinazolin-4-
ylamino)phenyl)prop-2-en-1-one (11d)
The compound 11d was prepared following the method
described for the preparation of the compound 11a, employing
4-(quinazolin-4-ylamino)benzaldehyde (3) (400 mg, 1.60 mmol)
and 4-bromoacetophenone (10d) (318 mg, 1.60 mmol) to afford
pure compound 11d, 473 mg in 69% yield. Mp: 127–129 C; 1H
NMR (400 MHz, DMSO-d6): d 7.37 (d, 1H, J= 15.4 Hz), 7.45
(d, 2H, J= 8.12 Hz), 7.49 (d, 2H, J= 8.12 Hz), 7.69–7.76 (m,
3H), 7.80–7.85 (m, 3H), 7.91 (d, 2H, J= 9.23 Hz), 8.49–8.53
(m, 1H), 8.76 (s, 1H), 9.56 (s, 1H); 13C NMR (400 MHz,
DMSO-d6): d 112.4, 119.3, 123.5, 125.2, 130.8, 133.4, 134.7,
134.9, 135.6, 136.2, 136.8, 137.3, 143.2, 147.5, 154.3, 162.7,
166.7, 185.3; MS (ESI): 431 [M+H]+.
2.4.5. Synthesis of (E)-1-(3-Bromophenyl)-3-(4-(quinazolin-4-
ylamino)phenyl)prop-2-en-1-one (11e)
The compound 11e was prepared following the method
described for the preparation of the compound 11a, employing
4-(quinazolin-4-ylamino)benzaldehyde (3) (400 mg, 1.60
mmol) and 3-bromoacetophenone (10e) (0.21 mL, 1.60 mmol)
to afford pure compound 11e, 466 mg in 68% yield. Mp:
130–132 C; 1H NMR (400 MHz, DMSO-d6): d 7.39 (d, 1H,
J= 15.3 Hz), 7.43 (t, 1H), 7.52 (d, 2H, J= 8.23 Hz),
7.64–7.78 (m, 6H), 7.83 (t, 1H), 8.44–8.49 (m, 2H), 8.56–8.59
(m, 1H), 8.79 (s, 1H), 9.58 (s, 1H); 13C NMR (400 MHz,
DMSO-d6): d 112.7, 119.6, 122.5, 126.2, 131.4, 133.7, 134.5,
134.9, 135.4, 136.6, 136.9, 137.5, 143.7, 147.8, 154.6, 162.9,
165.8, 184.5; MS (ESI): 431 [M+H]+.
2.4.6. Synthesis of (E)-1-(2-Fluoro-4-(trifluoromethyl)phenyl)-
3-(4-(quinazolin-4-ylamino)phenyl)prop-2-en-1-one (11f)
The compound 11f was prepared following the method
described for the preparation of the compound 11a, employing
4-(quinazolin-4-ylamino)benzaldehyde (3) (400 mg, 1.60 mmol)
and 1-(2-fluoro-4-(trifluoromethyl)phenyl)ethanone (10f)Please cite this article in press as: Madhavi, S. et al., Synthesis of chalcone incorpora
(2016), http://dx.doi.org/10.1016/j.jsps.2016.06.005(0.32 mL, 1.60 mmol) to afford pure compound 11f, 586 mg
in 83% yield. Mp: 140–142 C; 1H NMR (400 MHz,
DMSO-d6): d 7.28 (d, 1H, J= 15.7 Hz), 7.41 (d, 2H,
J= 8.19 Hz), 7.58–7.67 (m, 6H), 7.76 (t, 1H), 7.86–7.95
(m, 1H), 8.35–8.37 (m, 1H), 8.45–8.49 (m, 1H), 8.88 (s, 1H),
9.29 (s, 1H); 13C NMR (400 MHz, DMSO-d6): d 120.8,
121.3, 121.9, 122.4, 124.4, 124.9, 125.4, 127.4, 131.3, 131.9,
132.4, 133.7, 135.6, 142.3, 143.6, 145.6, 156.8, 161.3, 163.7,
165.6, 180.5; MS (ESI): 438 [M+H]+.
2.4.7. Synthesis of (E)-1-(4-(Trifluoromethyl)phenyl)-3-(4-
(quinazolin-4-ylamino)phenyl)prop-2-en-1-one (11g)
The compound 11g was prepared following the method
described for the preparation of the compound 11a, employing
4-(quinazolin-4-ylamino)benzaldehyde (3) (400 mg, 1.60 mmol)
and 1-(4-(trifluoromethyl)phenyl)ethanone (10g) (0.3 mL,
1.60 mmol) to afford pure compound 11g, 512 mg in
76% yield. Mp: 134–136 C; 1H NMR (400 MHz,
DMSO-d6): d 7.23 (d, 1H, J= 15.4 Hz), 7.35 (d, 2H,
J= 8.21 Hz), 7.57–7.68 (m, 5H), 7.78 (t, 1H), 8.65–8.69 (m,
5H), 8.85 (s, 1H), 9.25 (s, 1H); 13C NMR (400 MHz,
DMSO-d6): d 120.3, 121.4, 124.5, 124.8, 125.2, 125.9, 133.3,
133.6, 134.1, 134.5, 134.9, 135.3, 137.4, 142.4, 142.7, 147.5,
156.4, 160.7, 165.3, 182.5; MS (ESI): 420 [M+H]+.
2.4.8. Synthesis of (E)-1-(3-fluorophenyl)-3-(4-(quinazolin-4-
ylamino)phenyl)prop-2-en-1-one (11h)
The compound 11h was prepared following the method
described for the preparation of the compound 11a, employing
4-(quinazolin-4-ylamino)benzaldehyde (3) (400 mg, 1.60 mmol)
and 1-(3-fluorophenyl)ethanone (10h) (0.2 mL, 1.60 mmol)
to afford pure compound 11h, 472 mg in 80% yield.
Mp: 139–141 C; 1H NMR (400 MHz, DMSO-d6):
d 7.19 (d, 1H, J= 15.8 Hz), 7.37 (d, 2H, J= 8.45 Hz),
7.54–7.76 (m, 7H), 7.79 (t, 1H), 7.85–7.87 (m, 1H), 8.38 (m,
1H), 8.76 (s, 1H), 9.30 (s, 1H); 13C NMR (400 MHz,
DMSO-d6): d 119.4, 120.5, 121.6, 124.5, 126.7, 129.5, 130.3,
133.2, 133.7, 134.3, 134.6, 134.9, 135.6, 139.4, 142.4, 146.4,
155.7, 160.3, 162.4, 164.3, 180.4; MS (ESI): 370 [M+H]+.
2.4.9. Synthesis of (E)-1-(3,4-Dimethoxyphenyl)-3-(4-(quina-
zolin-4-ylamino)phenyl)prop-2-en-1-one (11i)
The compound 11i was prepared following the method
described for the preparation of the compound 11a, employing
4-(quinazolin-4-ylamino)benzaldehyde (3) (400 mg, 1.60
mmol) and 1-(3,4-dimethoxyphenyl)ethanone (10i) (288 mg,
1.60 mmol) to afford pure compound 11i, 511 mg in 77%
yield. Mp: 149–151 C; 1H NMR (400 MHz, DMSO-d6): d
3.76 (s, 3H), 3.83 (s, 3H), 7.45 (d, 1H, J= 15.5 Hz), 7.49 (d,
1H, J= 1.22 Hz), 7.54 (d, 2H, J= 8.93 Hz), 7.62–7.66 (m,
2H), 7.70–7.76 (m, 5H), 7.81–7.84 (t, 1H), 7.91–7.94 (m, 1H),
8.79 (s, 1H), 9.23 (s, 1H); 13C NMR (400 MHz, DMSO-d6):
d 56.8, 57.3, 118.5, 121.4, 124.8, 128.4, 128.9, 129.5, 131.6,
131.9, 132.3, 132.8, 134.5, 143.6, 147.4, 149.3, 151.8, 155.6,
160.3, 165.6, 179.9; MS (ESI): 412 [M+H]+.
2.4.10. Synthesis of (E)-1-(4-Methoxyphenyl)-3-(4-
(quinazolin-4-ylamino)phenyl)prop-2-en-1-one (11j)
The compound 11j was prepared following the method
described for the preparation of the compound 11a, employingted quinazoline derivatives as anticancer agents. Saudi Pharmaceutical Journal
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mmol) and 1-(4-methoxyphenyl)ethanone (10j) (240 mg,
1.60 mmol) to afford pure compound 11j, 492 mg in 80%
yield. Mp: 146–148 C; 1H NMR (400 MHz, DMSO-d6): d
3.85 (s, 3H), 7.39 (m, 3H), 7.46 (d, 2H, J= 8.26 Hz), 7.49
(d, 2H, J= 8.26 Hz), 7.63–7.70 (m, 3H), 7.75 (t, 1H); 7.85
(d, 2H, J= 9.12 Hz), 8.36 (m, 1H), 8.83 (s, 1H), 9.28
(s, 1H); 13C NMR (400 MHz, DMSO-d6): d 56.7, 110.4,
120.6, 122.4, 124.5, 125.4, 130.3, 131.8, 132.5, 132.8, 134.7,
142.5, 143.7, 151.3, 160.2, 163.5, 164.7, 180.6; MS (ESI): 382
[M+H]+.
2.5. Cytotoxicity – MTT assay
The cytotoxic activity of the compounds was determined using
MTT assay (Kamal et al., 2012). 1  104 cells/well were seeded
in 200 ll DMEM, supplemented with 10% FBS in each well of
96-well microculture plates and incubated for 24 h at 37 C in a
CO2 incubator. Compounds, diluted to the desired concentra-
tions in culture medium, were added to the wells with
respective vehicle control. After 48 h of incubation, 10 ll
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide) (5 mg/ml) was added to each well and the plates were
further incubated for 4 h. Then the supernatant from each well
was carefully removed, formazon crystals were dissolved in
100 ll of DMSO and absorbance at 540 nm wavelength was
recorded.
3. Results and discussion
3.1. Chemistry
Synthesis of these new chalcone incorporated quinazoline
derivatives (11a–11j) was shown in Scheme 1. The anthranilic
acid (4) was heated with formamide (5) in absolute ethanol
at 165 C for 4 h, to afford compound 6 with good yield.
The intermediate 6 was dissolved in 60 mL POCl3 and reflux
for 4 h, to afford pure 4-chloroquinazoline (7), which wasCO
2
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(2016), http://dx.doi.org/10.1016/j.jsps.2016.06.005coupled with 4-aminobenzaldehyde (8) in NMP, catalytic
amount of hydrochloric acid and heated for 1 h to afford pure
4-(quinazolin-4-ylamino)benzaldehyde (9). This aldehyde
intermediate (9) undergone aldol condensation with substi-
tuted acetophenones (10a–10j) in the presence of ethanol and
catalytic amount of piperidine at reflux for 4 h to afford pure
chalcone derivatives of quinazolines (11a–11j).
4. Biological evaluation
4.1. In vitro cytotoxic activity
The in vitro anticancer activities of all the synthesized target
molecules (11a–11j) were evaluated by MTT assay, wherein
selected four human cancer cell lines such as A549 (Human
alveolar adenocarcinoma cell line), MCF-7 (Human breast
adenocarcinoma cell line), HT-29 (Human Colorectal Adeno-
carcinoma Cell Line) and A375 (Melanoma cancer cell line).
The IC50 was calculated for these tested compounds in lM.
IC50 may be defined as the drug concentration that produced
50% inhibition of the cells. Combretastatin-A4 (CA-4) was
chosen as reference molecule. The cytotoxicities were expressed
as IC50 values presented in Table 1. Among the synthesized
compounds, 11 g exhibits most potent activity towards
HT-29, MCF 7 and A 549 cancer cell lines with IC50 values
0.13 lM, 0.17 lM and 0.10 lM than the control drug
Combretastatin-A4. While the compound 11f showed good
cytotoxicity with IC50 value 0.18 lM towards Human
Colorectal Adenocarcinoma Cell Line than the control drug,
the compound 11i exhibited maximum cytotoxic effect on
A549, MCF 7 and A375 with IC50 values 0.10 lM, 0.14 lM
and 0.19 lM than the positive control. Compound 11j exhib-
ited better anti-cancer activity with IC50 value 0.16 lM on
MCF 7 cell line than the standard drug. The remaining
compounds 11a, 11b, 11c, 11d, 11e and 11h also show
significant anti-cancer activities towards A549, HT-29, MCF
7 and A375 cell lines. The anti-cancer activity results of all
the synthesized compounds are shown in Table 1.N
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    1 hN
N
Cl
OHC
Me
OR
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N
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OR
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reflux, 4 h
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romethyl
thoxy
y
7
8
9
10a-j
11a-j
orporated Quinazoline derivatives.
ted quinazoline derivatives as anticancer agents. Saudi Pharmaceutical Journal
Table 1 Anticancer activity (IC50) data of chalcone-quinazo-
line compounds (11a–11j).
Compound A549 HT-29 MCF-7 A375
11a 2.67 4.67 3.78 –
11b – 12.6 – 5.87
11c 1.34 – 2.01 2.23
11d 3.67 2.11 – 2.30
11e 7.45 2.33 – –
11f 2.90 0.18 – 1.89
11g 0.10 0.13 0.17 1.34
11h 2.55 – – 9.34
11i 0.10 1.56 0.14 0.19
11j 2.10 2.89 0.16 1.37
Combretastatin-A4 0.11 0.93 0.18 0.21
‘‘–” indicate not active.
A549 – Human alveolar adenocarcinoma cell line.
HT-29 – Human Colorectal Adenocarcinoma Cell Line.
MCF-7 – Human breast adenocarcinoma cell line.
A375 – Melanoma cancer cell line.
Synthesis of chalcone incorporated quinazoline derivatives 55. Conclusion
In conclusion, we have synthesized a new chalcone incorpo-
rated quinazoline derivatives (11a–11j) and evaluated for their
anticancer activity against four human cancer cell lines (A549,
MCF-7, HT-29 and A375). Among them, the compounds 11f,
11g, 11i and 11j were showed more potent activity than posi-
tive control of combretastatin-A4. The concentrations of the
compounds which produce 50% inhibition of cell growth
(IC50) were compared with those of the standard drug, that
is, combretastatin-A4.
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